Suman Mukhopadhyay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suman Mukhopadhyay has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Lopez
Laura and Isaac Perlmutter Cancer Center 1 New York, New York
27 shared publications - Alireza Khodadadi-Jamayran
Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA
27 shared publications - Amanda P. Armstrong
Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, New York, New York
27 shared publications - Benjamin G. Neel
Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, USA
27 shared publications - Fiona Sherman
Laura and Isaac Perlmutter Cancer Center 1 New York, New York
27 shared publications - Hai Hu
Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, New York, New York
27 shared publications
Latest Publications
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S1 MaGeCK analysis of MRTX-849 CRISPR/Cas9 SL screens of NSCLC cell lines
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S1 MaGeCK analysis of MRTX-849 CRISPR/Cas9 SL screens of NSCLC cell lines
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S4 MaGeCK analysis of MRTX-849/TNO155 CRISPR/Cas9 screens of NSCLC cell lines
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S4 MaGeCK analysis of MRTX-849/TNO155 CRISPR/Cas9 screens of NSCLC cell lines
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S5 MaGeCK analysis of TNO155 CRISPR/Cas9 screens of NSCLC cell lines
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S5 MaGeCK analysis of TNO155 CRISPR/Cas9 screens of NSCLC cell lines
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-7 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Figures 1-7 including Figure legends
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-7 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Figures 1-7 including Figure legends
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S8 RNA-seq analysis of MTRX-849/SHP099-resistant tumor nodules from KCL mice
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S8 RNA-seq analysis of MTRX-849/SHP099-resistant tumor nodules from KCL mice
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S8 RNA-seq analysis of MTRX-849/SHP099-resistant tumor nodules from KCL mice
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S8 RNA-seq analysis of MTRX-849/SHP099-resistant tumor nodules from KCL mice
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S6 RNA-seq analysis of MTRX-849-resistant tumor nodules from KCL mice
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S6 RNA-seq analysis of MTRX-849-resistant tumor nodules from KCL mice
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S1 MaGeCK analysis of MRTX-849 CRISPR/Cas9 SL screens of NSCLC cell lines
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S1 MaGeCK analysis of MRTX-849 CRISPR/Cas9 SL screens of NSCLC cell lines
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S9 RPPA data from MRTX-849/SHP099-resistant tumor nodules in KCL mice
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Supplementary Table S9 RPPA data from MRTX-849/SHP099-resistant tumor nodules in KCL mice